I am not the only one who has articulated this thinking (3)
Pietrzykowska, MD, FACP, is a Board Certified Obesity Medicine Specialist, Physician Nutrition Specialist and Health Coach
110, 1745 (Academic Press, 2019)
Disclosure is provided in accordance with Federal Trade Commission (FTC) guidelines under 16 CFR Part 255 regarding endorsements and testimonials in advertising
For type 2 diabetes management , NICE guidance (NG28) recommends GLP-1 agonists as second- or third-line therapy when metformin and other oral agents provide inadequate glycaemic control, or as an alternative to insulin in appropriate patients
Other Possible Causes Nausea during semaglutide therapy is usually attributable to the medication itself, but other causes should be ruled out